SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-027426
Filing Date
2023-08-04
Accepted
2023-08-04 09:10:29
Documents
15
Period of Report
2023-08-04
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K ovid-20230804.htm   iXBRL 8-K 30124
2 EX-99.1 ovid2023q2exhibit991.htm EX-99.1 71900
7 img34400995_0a.jpg GRAPHIC 17099
  Complete submission text file 0001628280-23-027426.txt   270703

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ovid-20230804.xsd EX-101.SCH 2152
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ovid-20230804_def.xml EX-101.DEF 2891
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ovid-20230804_lab.xml EX-101.LAB 26895
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ovid-20230804_pre.xml EX-101.PRE 14676
9 EXTRACTED XBRL INSTANCE DOCUMENT ovid-20230804_htm.xml XML 2394
Mailing Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001
Business Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001 212-776-4381
Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)

IRS No.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38085 | Film No.: 231142374
SIC: 2834 Pharmaceutical Preparations